7A9U

N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 3-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)-N-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-8-yl)propanamide

This is a non-PDB format compatible entry.

Summary for 7A9U

• Entry DOI: 10.2210/pdb7a9u/pdb
• Descriptor: Bromodomain-containing protein 4, 3-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)-N-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-8-yl)propanamide, 1,2-ETHANEDIOL, ... (4 entities in total)
• Functional Keywords: inhibitor, histone, epigenetic reader, bromodomain, brd4, bromodomain containing protein 4, antagonist, transcription
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 1
• Total formula weight: 15583.93

Authors

Chung, C. (deposition date: 2020-09-02, release date: 2020-10-21, Last modification date: 2024-05-01)

Primary citation

Grant, E.K.,Fallon, D.J.,Hann, M.M.,Fantom, K.G.M.,Quinn, C.,Zappacosta, F.,Annan, R.S.,Chung, C.W.,Bamborough, P.,Dixon, D.P.,Stacey, P.,House, D.,Patel, V.K.,Tomkinson, N.C.O.,Bush, J.T.
A Photoaffinity-Based Fragment-Screening Platform for Efficient Identification of Protein Ligands.
Angew.Chem.Int.Ed.Engl., 59:21096-21105, 2020

PubMed Abstract: Advances in genomic analyses enable the identification of new proteins that are associated with disease. To validate these targets, tool molecules are required to demonstrate that a ligand can have a disease-modifying effect. Currently, as tools are reported for only a fraction of the proteome, platforms for ligand discovery are essential to leverage insights from genomic analyses. Fragment screening offers an efficient approach to explore chemical space. Presented here is a fragment-screening platform, termed PhABits (PhotoAffinity Bits), which utilizes a library of photoreactive fragments to covalently capture fragment-protein interactions. Hits can be profiled to determine potency and the site of crosslinking, and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is envisioned to be widely applicable to novel protein targets, identifying starting points in the development of therapeutics.

PubMed: 32745361
DOI: 10.1002/anie.202008361

Experimental method

X-RAY DIFFRACTION (1.444 Å)